The Safety of Intrathecal Therapy in the Treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Phavina A Akhom(Vanderbilt University Medical Center), Adetola A. Kassim(Vanderbilt University), Eden Biltibo(Vanderbilt University Medical Center), Nancy Clayton Long(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University Medical Center), Shakthi Bhaskar(Vanderbilt University Medical Center), James H. Jerkins(Vanderbilt University Medical Center), Olalekan O. Oluwole(Vanderbilt University), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Vivek Patel(Vanderbilt University Medical Center), Katie S. Gatwood(Vanderbilt University Medical Center), Brittney Baer(Vanderbilt University Medical Center), G. Allan Johnson(Duke University), Bipin N. Savani(Vanderbilt University Medical Center), David Morgan(Vanderbilt University Medical Center), Andrew Jallouk(Vanderbilt University Medical Center), Nur Ali(Vanderbilt University Medical Center), Brian Hoeynck(Vanderbilt University Medical Center)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782